Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the role of Chief Medical Officer (CMO). Dr. Zhu will oversee all clinical development activities related to the firm’s pipeline candidates, succeeding Dr. Peng Bin who has recently retired.
Dr. Zhu’s Impressive Background in Clinical Development
Dr. Zhu brings a wealth of experience to EpimAb Biotherapeutics, having previously served as CMO at China-based MaxiNovel Pharmaceuticals. Prior to this, he held positions in clinical development and translational medicine at renowned pharmaceutical companies such as Roche, Takeda, and Henlius. His expertise in these areas will be instrumental in advancing EpimAb’s pipeline and driving the company’s clinical strategies forward.
Leadership Transition and Future Prospects
The appointment of Dr. Zhu signifies a strategic move for EpimAb Biotherapeutics as they continue to expand their clinical development efforts. His extensive experience in the biotech industry, particularly in the areas of clinical development and translational medicine, positions him well to lead the company’s clinical initiatives and contribute to the success of their pipeline candidates.-Fineline Info & Tech
